A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention
Chen AC, Martin AJ, Choy B
Published in New England Journal of Medicine
Key Findings
Nicotinamide 500 mg twice daily reduced new non-melanoma skin cancers by 23% over 12 months in high-risk patients, with benefit lost after stopping.
Conclusions
Best-evidenced use of niacinamide is skin-cancer chemoprevention in high-risk adults.
Limitations
Benefit not sustained after discontinuation.
Supplements Studied
Nicotinamide reduced new non-melanoma skin cancers by 23% over 12 months in high-risk patients.
Nicotinamide reduced the rate of new non-melanoma skin cancers by 23% compared with placebo.
Nicotinamide reduced new non-melanoma skin cancers by 23% versus placebo
Outcomes Measured
Nicotinamide reduced new non-melanoma skin cancers by 23% in high-risk patients.
Oral nicotinamide was safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients.
Nicotinamide reduced new non-melanoma skin cancers by 23% versus placebo
Nicotinamide reduced new non-melanoma skin cancers by 23% and actinic keratoses by 11-20% versus placebo
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.